Daniel L Morganstein
Overview
Explore the profile of Daniel L Morganstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mavroeidis V, Knapton J, Saffioti F, Morganstein D
World J Diabetes
. 2024 Apr;
15(4):598-605.
PMID: 38680702
Pancreatic surgery units undertake several complex operations, albeit with considerable morbidity and mortality, as is the case for the management of complicated acute pancreatitis or chronic pancreatitis. The centralisation of...
2.
Cortellini A, DAlessio A, Cleary S, Buti S, Bersanelli M, Bordi P, et al.
Clin Cancer Res
. 2023 May;
29(14):2714-2724.
PMID: 37125965
Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large...
3.
Percik R, Criseno S, Adam S, Young K, Morganstein D
Endocr Connect
. 2023 Mar;
12(5).
PMID: 36884258
Checkpoint inhibitors are now widely used in the management of many cancers. Endocrine toxicity is amongst the most common side effects. These endocrinopathies differ from most other immune-related toxicities in...
4.
Joharatnam-Hogan N, Morganstein D
J Hum Nutr Diet
. 2022 Jun;
36(2):504-513.
PMID: 35748508
Diabetes and cancer are both common and increasingly prevalent conditions, but emerging epidemiological evidence confirms that the risk of developing a number of common cancers is increased in those with...
5.
Percik R, Larkin J, Morganstein D
Lancet Oncol
. 2021 Jul;
22(7):905-907.
PMID: 34197741
No abstract available.
6.
Anderson B, Morganstein D
Endocr Connect
. 2021 Feb;
10(3):R116-R124.
PMID: 33544091
Immune checkpoint inhibitors are now widely used in the treatment of multiple cancers. The major toxicities of these treatments are termed immune-related adverse events and endocrine dysfunction is common. Thyroid...
7.
Morganstein D, Larkin J
Clin Med (Lond)
. 2020 Sep;
20(5):e139.
PMID: 32934060
No abstract available.
8.
Nogueira E, Newsom-Davis T, Morganstein D
Ther Adv Endocrinol Metab
. 2020 Jan;
10:2042018819896182.
PMID: 31903179
Immunotherapy with checkpoint inhibitors has transformed the treatment of cancer, but frequently results in immune-mediated adverse events affecting multiple organs, amongst which endocrine adverse events are frequent. The patterns of...
9.
Morganstein D, Parker M
Expert Rev Endocrinol Metab
. 2018 Oct;
2(6):797-807.
PMID: 30290475
Understanding the molecular regulation of metabolism will lead to a better understanding of the pathogenesis and treatment of common metabolic conditions, including obesity and diabetes. Nuclear receptors are a family...
10.
Morganstein D, Wu P, Mane M, Fisk N, White R, Parker M
Cell Res
. 2010 Jan;
20(4):434-44.
PMID: 20101261
We investigated the ability of fetal mesenchymal stem cells (fMSCs) to differentiate into brown and white adipocytes and compared the expression of a number of marker genes and key regulatory...